# OnCo record rejuv-tx-infection-by-phase (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-tx-infection-by-phase/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-tx-infection-by-phase" ;
  schema:name "Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it"@en ;
  schema:alternateName "infection after HSCT"@en, "post-transplant prophylaxis"@en, "CMV prophylaxis"@en, "PJP prophylaxis"@en, "infection after CAR-T"@en ;
  schema:description "Which infections threaten someone after a transplant depends almost entirely on how long it has been, because the immune system returns in a known order: bacteria and fungi first, viruses such as cytomegalovirus in the middle months, encapsulated bacteria later. The preventive medicines are matched to those phases."@en ;
  schema:url <https://onco.cc/technologies/rejuv-tx-infection-by-phase/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Opportunistic_infection> ;
  schema:citation <https://doi.org/10.1016/j.bbmt.2009.06.019>, <https://doi.org/10.1056/NEJMoa1706640>, <https://doi.org/10.1182/blood-2017-07-793760>, <https://doi.org/10.1111/tid.13619>, <https://doi.org/10.1093/cid/ciz490>, <https://doi.org/10.3389/fimmu.2016.00507> ;
  onco:status "standard-of-care" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "evidence:strong", "immune", "infection" ;
  onco:related <https://onco.cc/technologies/rejuv-tx-immune-reconstitution-timeline/>, <https://onco.cc/technologies/rejuv-tx-b-cell-aplasia-and-immunoglobulin/>, <https://onco.cc/technologies/rejuv-tx-revaccination/>, <https://onco.cc/technologies/rejuv-tx-prolonged-cytopenias/>, <https://onco.cc/technologies/gvhd-prophylaxis/>, <https://onco.cc/technologies/gvhd-chronic-overview/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/tocilizumab/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/cytopenias/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .